Your browser doesn't support javascript.
loading
Associations between lipoprotein(a), oxidized phospholipids, and extracoronary vascular disease.
Bellomo, Tiffany R; Liu, Yuxi; Gilliland, Thomas C; Miksenas, Hannah; Haidermota, Sara; Wong, Megan; Hu, Xingdi; Cristino, Joaquim Rosado; Browne, Auris; Plutzky, Jorge; Tsimikas, Sotirios; Januzzi, James L; Natarajan, Pradeep.
Afiliação
  • Bellomo TR; Division of Vascular and Endovascular Surgery, Massachusetts General Hospital, Boston, MA, USA.
  • Liu Y; Division of Cardiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Gilliland TC; Division of Cardiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Program in Medical and Population Genetics and the Cardiovascular Disease Initiative, Broad Institute of Harvard and MIT, Cambridge, MA, USA.
  • Miksenas H; Division of Cardiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Haidermota S; Division of Cardiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Wong M; Division of Cardiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Hu X; Novartis Pharmaceuticals Corporation, Novartis, East Hanover, NJ, USA.
  • Cristino JR; Novartis Pharmaceuticals Corporation, Novartis, East Hanover, NJ, USA.
  • Browne A; Novartis Pharmaceuticals Corporation, Novartis, East Hanover, NJ, USA.
  • Plutzky J; Division of Cardiology, Brigham and Women's Hospital, Boston, Harvard Medical School, Boston, MA, USA.
  • Tsimikas S; Sulpizio Cardiovascular Center, University of California San Diego, La Jolla, CA, USA.
  • Januzzi JL; Division of Cardiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Cardiology Division, Baim Institute for Clinical Research, Boston, MA, USA.
  • Natarajan P; Division of Cardiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Program in Medical and Population Genetics and the Cardiovascular Disease Initiative, Broad Institute of Harvard and MIT, Cambridge, MA, USA. Electronic address: pnatarajan@mgh.harvard.edu.
J Lipid Res ; 65(7): 100585, 2024 Jul.
Article em En | MEDLINE | ID: mdl-38942114
ABSTRACT
The roles of lipoprotein(a) [Lp(a)] and related oxidized phospholipids (OxPLs) in the development and progression of coronary disease is known, but their influence on extracoronary vascular disease is not well-established. We sought to evaluate associations between Lp(a), OxPL apolipoprotein B (OxPL-apoB), and apolipoprotein(a) (OxPL-apo(a)) with angiographic extracoronary vascular disease and incident major adverse limb events (MALEs). Four hundred forty-six participants who underwent coronary and/or peripheral angiography were followed up for a median of 3.7 years. Lp(a) and OxPLs were measured before angiography. Elevated Lp(a) was defined as ≥150 nmol/L. Elevated OxPL-apoB and OxPL-apo(a) were defined as greater than or equal to the 75th percentile (OxPL-apoB ≥8.2 nmol/L and OxPL-apo(a) ≥35.8 nmol/L, respectively). Elevated Lp(a) had a stronger association with the presence of extracoronary vascular disease compared to OxPLs and was minimally improved with the addition of OxPLs in multivariable models. Compared to participants with normal Lp(a) and OxPL concentrations, participants with elevated Lp(a) levels were twice as likely to experience a MALE (odds ratio 2.14, 95% confidence interval 1.03, 4.44), and the strength of the association as well as the C statistic of 0.82 was largely unchanged with the addition of OxPL-apoB and OxPL-apo(a). Elevated Lp(a) and OxPLs are risk factors for progression and complications of extracoronary vascular disease. However, the addition of OxPLs to Lp(a) does not provide additional information about risk of extracoronary vascular disease. Therefore, Lp(a) alone captures the risk profile of Lp(a), OxPL-apoB, and OxPL-apo(a) in the development and progression of atherosclerotic plaque in peripheral arteries.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Oxirredução / Fosfolipídeos / Lipoproteína(a) Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Oxirredução / Fosfolipídeos / Lipoproteína(a) Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2024 Tipo de documento: Article